Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

BACKGROUND: Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis, Gilmar, dos Santos Moreira-Silva, Eduardo Augusto, Silva, Daniela Carla Medeiros, Thabane, Lehana, Milagres, Aline Cruz, Ferreira, Thiago Santiago, dos Santos, Castilho Vitor Quirino, de Souza Campos, Vitoria Helena, Nogueira, Ana Maria Ribeiro, de Almeida, Ana Paula Figueiredo Guimaraes, Callegari, Eduardo Diniz, de Figueiredo Neto, Adhemar Dias, Savassi, Leonardo Cançado Monteiro, Simplicio, Maria Izabel Campos, Ribeiro, Luciene Barra, Oliveira, Rosemary, Harari, Ofir, Forrest, Jamie I, Ruton, Hinda, Sprague, Sheila, McKay, Paula, Glushchenko, Alla V, Rayner, Craig R, Lenze, Eric J, Reiersen, Angela M, Guyatt, Gordon H, Mills, Edward J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550952/
https://www.ncbi.nlm.nih.gov/pubmed/34717820
http://dx.doi.org/10.1016/S2214-109X(21)00448-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550952/
https://www.ncbi.nlm.nih.gov/pubmed/34717820
http://dx.doi.org/10.1016/S2214-109X(21)00448-4

Ejemplares similares